Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,301 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,832 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00521261 | Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | withdrawn | Phase 1 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Mar 5, 2014 | clinicaltrials |
| NCT00791011 | Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | completed | Phase 1 | 33 | AmgenINDUSTRY | 0 | Mar 5, 2014 | clinicaltrials |
| NCT00866346 | PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 4, 2014 | clinicaltrials |
| NCT01256073 | A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia | completed | Phase 1 | 21 | Innate PharmaINDUSTRY | 1 | Feb 28, 2014 | clinicaltrials |
| NCT00943592 | Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 82 | University of ChicagoOTHER | 1 | Feb 27, 2014 | clinicaltrials |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00004932 | STI571 in Treating Patients With Recurrent Leukemia | completed | Phase 1 | 31 | Children's Oncology GroupNETWORK | 7 | Feb 21, 2014 | clinicaltrials |
| NCT00028899 | Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 47 | Children's Oncology GroupNETWORK | 3 | Feb 20, 2014 | clinicaltrials |
| NCT00083070 | Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia | completed | Phase 1 | 16 | Children's Oncology GroupNETWORK | 2 | Feb 20, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT00396968 | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | withdrawn | Phase 1 / Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Feb 11, 2014 | clinicaltrials |
| NCT01841489 | A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics | completed | Phase 1 | 56 | Gilead SciencesINDUSTRY | 1 | Feb 7, 2014 | clinicaltrials |
| NCT00113048 | Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies | terminated | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 5, 2014 | clinicaltrials |
| NCT00125840 | Clofarabine in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 5, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 | clinicaltrials |
| NCT01455506 | PRO#0118: Decitabine Plus Mini Flu-Bu | completed | Phase 1 | 20 | Hackensack Meridian HealthOTHER | 1 | Feb 4, 2014 | clinicaltrials |
| NCT00458679 | Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells(PRIMAL) | completed | Phase 1 | 6 | Baylor College of MedicineOTHER | 1 | Feb 3, 2014 | clinicaltrials |
| NCT01168752 | Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma | completed | Phase 1 | 81 | Debiopharm International SAINDUSTRY | 1 | Feb 3, 2014 | clinicaltrials |
| NCT01280786 | Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 36 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Feb 3, 2014 | clinicaltrials |
| NCT01022255 | Autologous Vaccine for Follicular Lymphoma | completed | Phase 1 | 28 | Icon Genetics GmbHINDUSTRY | 1 | Jan 30, 2014 | clinicaltrials |
| NCT01273090 | Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma | completed | Phase 1 | 34 | Children's Oncology GroupNETWORK | 2 | Jan 30, 2014 | clinicaltrials |
| NCT00978523 | Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma | completed | Phase 1 | 35 | Arno TherapeuticsINDUSTRY | 2 | Jan 29, 2014 | clinicaltrials |
| NCT01884428 | Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | unknown | Phase 1 | 24 | Armando Santoro, MDOTHER | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00725634 | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma(P05538) | completed | Phase 1 | 41 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00727831 | Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | completed | Phase 1 / Phase 2 | 4 | University College, LondonOTHER | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00679536 | Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors | unknown | Phase 1 / Phase 2 | 30 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Jan 23, 2014 | clinicaltrials |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 58 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00093483 | Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 61 | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01251250 | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jan 13, 2014 | clinicaltrials |
| NCT00028613 | Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma | completed | Phase 1 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 9, 2014 | clinicaltrials |
| NCT00242515 | T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | unknown | Phase 1 / Phase 2 | 16 | National University Hospital, SingaporeOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00590603 | Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma(AAV) | terminated | Phase 1 | 25 | Duke UniversityOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00769288 | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2014 | clinicaltrials |
| NCT01478074 | ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Altor BioScienceINDUSTRY | 1 | Jan 3, 2014 | clinicaltrials |
| NCT01068301 | A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | completed | Phase 1 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Jan 1, 2014 | clinicaltrials |
| NCT01479023 | Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00004036 | Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer | unknown | Phase 1 | 30 | The Cleveland ClinicOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00040950 | Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00006100 | Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma | unknown | Phase 1 | — | Milton S. Hershey Medical CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00007839 | Beta Alethine in Treating Patients With Low-Grade Lymphoma | unknown | Phase 1 / Phase 2 | — | LifeTime PharmaceuticalsINDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00041379 | Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | — | LifeTime PharmaceuticalsINDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00923234 | Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes(AZALE) | terminated | Phase 1 | — | Technische Universität DresdenOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00005845 | Tipifarnib in Treating Patients With Myelodysplastic Syndromes | completed | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00019708 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00070239 | Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies | terminated | Phase 1 | 100 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00033423 | Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 | 18 | University of Alabama at BirminghamOTHER | 1 | Dec 13, 2013 | clinicaltrials |
| NCT01488344 | Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 140 | University Hospital MuensterOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT00672152 | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation(WT-1) | terminated | Phase 1 | 8 | Michael Morse, MDOTHER | 1 | Dec 10, 2013 | clinicaltrials |
Data updated 24 days agoSource updated Mar 5, 2014source: clinicaltrials